Cargando…

Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies

Detalles Bibliográficos
Autores principales:	Jakovljevic, Mihajlo, Yamada, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613116/ https://www.ncbi.nlm.nih.gov/pubmed/28983250 http://dx.doi.org/10.3389/fphar.2017.00662

Ejemplares similares

Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II
por: Jakovljevic, Mihajlo, et al.
Publicado: (2023)

Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion
por: Iskrov, Georgi, et al.
Publicado: (2016)

Commentary: Patient Cost Sharing and Medical Expenditures for the Elderly
por: Jakovljevic, Mihajlo
Publicado: (2016)

Situation, Impacts, and Future Challenges of Tobacco Control Policies for Youth: An Explorative Systematic Policy Review
por: Ranabhat, Chhabi Lal, et al.
Publicado: (2019)

Budget Impact of Publicly Reimbursed Prescription Medicines in the Republic of Srpska
por: Petrusic, Tamara, et al.
Publicado: (2015)

Editorial: Insights in health economics: 2021
por: Jakovljevic, Mihajlo, et al.
Publicado: (2022)

Reimbursement decision-making system in Poland systematically compared to other countries
por: Mela, Aneta, et al.
Publicado: (2023)

Editorial: Shaping with data: Using pharmacoepidemiology to shape pharmaceutical policy and clinical decision-making
por: Tadrous, Mina, et al.
Publicado: (2022)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Self-Assessed Health and Socioeconomic Inequalities in Serbia: Data from 2013 National Health Survey
por: Radevic, Svetlana, et al.
Publicado: (2016)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices
por: Reed, Shelby D., et al.
Publicado: (2007)

Editorial: Global excellence in health economics: Asia and Australasia
por: Jakovljevic, Mihajlo, et al.
Publicado: (2023)

The New and Old Europe: East-West Split in Pharmaceutical Spending
por: Jakovljevic, Mihajlo, et al.
Publicado: (2016)

Editorial: Global Population Aging - Health Care, Social and Economic Consequences
por: Ogura, Seiritsu, et al.
Publicado: (2018)

Medical Cost of Colorectal Cancer Services in Serbia Between 2014 and 2017: National Data Report
por: Vekic, Berislav, et al.
Publicado: (2019)

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions
por: Simeonidis, Stavros, et al.
Publicado: (2019)

Editorial: Emerging Markets’ Health and Pharmaceutical Sectors at the Dawn of a Potential Global Financial Crisis of early 2020s
por: Jakovljevic, Mihajlo, et al.
Publicado: (2022)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

Editorial: Big data shaping clinical trial landscape—Greater role for pharmacoeconomics in Asia
por: Jakovljevic, Mihajlo, et al.
Publicado: (2022)

Commentary: Do health care workforce, population, and service provision significantly contribute to the total health expenditure? An econometric analysis of Serbia
por: Jakovljevic, Mihajlo, et al.
Publicado: (2017)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
por: Tesar, Tomas, et al.
Publicado: (2019)

Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012)

Growth of Global Health Spending Share in Low and Middle Income Countries
por: Jakovljevic, Mihajlo, et al.
Publicado: (2016)

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States
por: Lemke, Lauren K., et al.
Publicado: (2023)

Editorial: Global population aging – Health care, social and economic consequences, volume II
por: Jakovljevic, Mihajlo, et al.
Publicado: (2023)

High Inequalities Associated With Socioeconomic Deprivation in Cardiovascular Disease Burden and Antihypertensive Medication in Hungary
por: Boruzs, Klára, et al.
Publicado: (2018)

Reimbursed Medication Adherence Enhancing Interventions in European Countries: Results of the EUREcA Study
por: Ágh, Tamás, et al.
Publicado: (2022)

The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling"
por: Kim, Hansoo, et al.
Publicado: (2020)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

Critical Reflections on Reimbursement and Access of Advanced Therapies
por: Simoens, Steven, et al.
Publicado: (2022)

Clinical and economic impact of changing reimbursement criteria for statin treatment among patients with type 2 diabetes mellitus in South Korea
por: Kim, Siin, et al.
Publicado: (2022)

Editorial: New Technologies in Cancer Diagnostics and Therapeutics
por: Li, Haichang, et al.
Publicado: (2021)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

The Dilemma of Medical Reimbursement Policy in Rural China: Spatial Variability between Reimbursement Region and Medical Catchment Area
por: Dong, Yongqing, et al.
Publicado: (2019)

Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
por: Kardas, Przemysław, et al.
Publicado: (2022)

Satisfaction with Health Services among the Citizens of Serbia
por: Mihailovic, Natasa M., et al.
Publicado: (2017)

When cure becomes an illness—abuse of addictive prescription medicines
por: Jakovljevic, Mihajlo (Michael), et al.
Publicado: (2015)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
por: Vella Bonanno, Patricia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vhc02up05aaoih8eu071qk3gkh